← Back to Search

Corticosteroid

Dexamethasone for Multiple Myeloma (INTREPID-1 Trial)

Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights

INTREPID-1 Trial Summary

This trial is testing two new treatments for patients with a certain type of blood cancer who have already tried other treatments.

Eligible Conditions
  • Multiple Myeloma

INTREPID-1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dexamethasone
Incidence of treatment-emergent adverse events
Incidence of treatment-related adverse events for all subjects on continued oprozomib treatment
+1 more
Secondary outcome measures
Area under the concentration-time curve
Best overall response
Duration of response
+4 more

Side effects data

From 2013 Phase 4 trial • 122 Patients • NCT01474915
2%
Deep Vein Thrombosis
2%
Cerebrospinal fluid leak
2%
Fever
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ondansetron
Aprepitant

INTREPID-1 Trial Design

4Treatment groups
Experimental Treatment
Group I: Part 2 Arm 2Experimental Treatment3 Interventions
Oprozomib (Gastro-retentive) plus pomalidomide and dexamethasone
Group II: Part 2 Arm 1Experimental Treatment3 Interventions
Oprozomib (Immediate release) plus pomalidomide and dexamethasone
Group III: Part 1 Arm 2Experimental Treatment2 Interventions
Oprozomib (Gastro-retentive) plus dexamethasone
Group IV: Part 1 Arm 1Experimental Treatment2 Interventions
Oprozomib (Immediate Release) plus dexamethasone
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Immediate Release (IR) Formulation
2017
Completed Phase 1
~70
Gastro-Retentive (GR) Formulation
2017
Completed Phase 1
~70
Dexamethasone
2007
Completed Phase 4
~2590
Pomalidomide
2011
Completed Phase 2
~1020

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,370 Previous Clinical Trials
1,377,627 Total Patients Enrolled
96 Trials studying Multiple Myeloma
20,679 Patients Enrolled for Multiple Myeloma
MDStudy DirectorAmgen
913 Previous Clinical Trials
924,070 Total Patients Enrolled
44 Trials studying Multiple Myeloma
11,284 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
2017. "Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02939183.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top